Product Details
| Product Name:
BD750 |
CAS No.:
892686-59-8 |
| Purity:
99.76% |
Supply Ability:
10g |
| Release date:
2025/08/22 |
Product Introduction
Bioactivity
| Name | BD750 |
| Description | BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in mouse and human T cells, respectively) |
| Animal Research | Female C57BL/6 mice (10 wks old, 19-21 g).Dosage with 20 μM, and administration:IV, treated DC on d 7, 11 and 15 post the first PTX injection (dpi 7, 11 and 15)[1]. |
| In vitro | Following BD750 treatment, LPS-induced maturation of DC, allogeneic T cell proliferation, Th1 and Th17 cell functional differentiation, the STAT5 and AKT activation were determined.?The effect of tolDC loaded with antigen peptide on the development and severity of EAE and their splenic Th1 and Th17 cell responses were determined.?In comparison with LPS-induced mature DC (mDC), BD750 treatment induced tolDC with lower expression levels of costimulatory molecules and pro-inflammatory cytokines and lower levels of STAT5 phosphorylation.?TolDC inhibited allogeneic T cell proliferation and reduced Th1 and Th17 responses[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 27.5 mg/mL (101.35 mM), Sonication is recommended.
|
| Keywords | STAT5 | STAT | Janus kinase | JAK3 | JAK | Inhibitor | inhibit | Immunosuppressant | cell | BD-750 | BD750 | BD 750 |
| Inhibitors Related | Delgocitinib | Nifuroxazide | Tofacitinib Citrate | Fludarabine | Niclosamide | Ruxolitinib phosphate | Balsalazide disodium dihydrate | CASIN | Diosgenin | Niclosamide olamine | Artesunate | Alantolactone |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | NO PAINS Compound Library | Stem Cell Differentiation Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1186426-66-3
$43.00 / 1mg
-
CAS:19309-14-9
$30.00 / 10mg
-
CAS:571203-78-6
$41.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States